Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Share Price Pass Below 200 Day Moving Average – Here’s What Happened

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $31.45 and traded as low as $27.24. Lakefront Biotherapeutics American Depositary Shares shares last traded at $27.67, with a volume of 69,614 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Royal Bank Of Canada increased their price target on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 24th. Zacks Research cut Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a research note on Thursday, February 26th. UBS Group restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Finally, Wall Street Zen cut Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Lakefront Biotherapeutics American Depositary Shares currently has an average rating of “Hold” and an average price target of $36.50.

Lakefront Biotherapeutics American Depositary Shares Trading Up 0.7%

The firm has a market cap of $1.82 billion, a P/E ratio of -19.62 and a beta of 0.25. The business has a 50 day moving average of $28.97 and a two-hundred day moving average of $31.45.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion for the quarter. On average, sell-side analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. ABC Arbitrage SA bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the first quarter worth $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the first quarter worth $248,000. QRG Capital Management Inc. increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% in the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after purchasing an additional 3,535 shares during the period. XTX Topco Ltd increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 92.6% in the fourth quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock worth $759,000 after purchasing an additional 11,162 shares during the period. Finally, Millennium Management LLC increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 121.9% in the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock worth $11,097,000 after purchasing an additional 186,452 shares during the period. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.